1 |
Hughes RA, Cornblath DR. Guillain-Barre syndrome. Lancet 2005;366:1653-1666.
DOI
|
2 |
Rudnicki SA, Dalmau J. Paraneoplastic syndromes of the peripheral nerves. Curr Opin Neurol 2005;18:598-603.
DOI
|
3 |
Graus F, Delattre J, Antoine J, Dalmau J, Giometto B, Grisold W, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004;75:1135-1140.
DOI
|
4 |
Vigliani M-C, Magistrello M, Polo P, Mutani R, Chio A. Risk of cancer in patients with Guillain-Barre syndrome (GBS). J Neurol 2004;251:321-326.
DOI
|
5 |
Cicero G, Fulfaro F, Caraceni A, Arcara C, Badalamenti G, Intrivici C, et al. A case of guillain-barre syndrome in a patient with non small cell lung cancer treated with chemotherapy. J Chemother 2006;18:325-327.
DOI
|
6 |
Navani V, Webster D, Williams SK, Agranoff D. Guillain-Barre syndrome as a paraneoplastic manifestation of disseminated squamous cell carcinoma. BMJ Case Rep 2013;2013. pii: bcr2013009700.
|
7 |
Naveed S, Okoli K, Hollingsworth J, Kasmani R. Guillain-Barre syndrome as a paraneoplastic manifestation of small-cell carcinoma of lung. South Med J 2010;103:156-158.
DOI
|
8 |
Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008;13:27-46.
DOI
|
9 |
Kusunoki S, Hitoshi S, Kaida KI, Arita M, Kanazawa I. Monospecific anti-GD1b IgG is required to induce rabbit ataxic neuropathy. Ann Neurol 1999;45:400-403.
DOI
|
10 |
Miyazaki T, Kusunoki S, Kaida K, Shiina M, Kanazawa I. Guillain-Barre syndrome associated with IgG monospecific to ganglioside GD1b. Neurology 2001;56:1227-1229.
DOI
|